Moody's Downgrades Aegis Toxicology Sciences Corporation's PDR to D-PD

Strategic Insights -

Aegis Toxicology Sciences Corporation, a privately-owned specialty toxicology laboratory, has seen its Probability of Default Rating (PDR) downgraded to D-PD by Moody's Investors Service due to failure to make a scheduled principal payment on its senior secured first lien term loan. The company's Corporate Family Rating (CFR) remains at Caa3, and the outlook remains stable. This downgrading reflects Aegis's inability to refinance or repay its term loan by its maturity date, leading to a payment default.

Key Takeaways:

  • Moody's downgraded Aegis's PDR to D-PD due to failure to make a scheduled principal payment on its senior secured first lien term loan on May 9, 2025.
  • The company's Corporate Family Rating (CFR) remains at Caa3, and the outlook remains stable.
  • Aegis entered into a forbearance agreement with its senior secured first lien term loan lenders after missing its principal payment at maturity, which allows for a 45-day grace period on the payment.
  • Governance considerations are material to the rating action, with Moody's viewing the missed payment as a default, regardless of the forbearance agreement.
  • Aegis's Caa3 CFR is constrained by very high refinancing risk, high financial leverage, small scale relative to larger competitors, and revenue concentration in niche toxicology testing.
  • The toxicology industry faces exposure to pricing pressure and potential reimbursement rate cuts in the coming years.
  • Partially mitigating some of these constraints, the company's ratings are supported by its ability to generate slightly positive free cash flow, limited capital expenditure requirements, and stable demand for its services.
  • Aegis's liquidity will remain weak until it refinances its term loan, with approximately $16 million of cash as of September 30, 2024.
  • The company's revolving credit facility expired in 2023, so there is no external source of funding available to Aegis.

Statistics:

  • Aegis generated revenue of roughly $132 million in the twelve months ended September 30, 2024.
  • The company's cash balance as of September 30, 2024, is approximately $16 million.
  • Aegis's senior secured first lien term loan is rated Caa3, equivalent to the company's Caa3 Corporate Family Rating.
  • Moody's expects the company to generate minimal free cash flow in the next 12 months.
  • The company's revolving credit facility expired in 2023.

Sources:

  • Moody's Ratings (Moody's), News Release, dated [date not specified]
  • Aegis Toxicology Sciences Corporation's financial statements, as of September 30, 2024
  • Moody's Ratings Methodology, Business and Consumer Services, published in November 2021, available at https://ratings.moodys.com/rmc-documents/356424
  • Rating Methodologies page on https://ratings.moodys.com